Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Zander

Showing results (411-420 of 456) with videos related to

Pageof 46
Sort By:
Blood|May 22, 2010
Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosisHaefaa Alchalby, Anita Badbaran, Tatjana Zabelina, et al.
Bone Marrow Transplantation|July 9, 2009
Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cellsM Lioznov, J El-Cheikh, F Hoffmann, et al.
Haematologica|May 25, 2011
Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myelomaDjordje Atanackovic, Jens Panse, York Hildebrandt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 29, 2008
Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-upA R Zander, C Schmoor, N Kröger, et al.
Bone Marrow Transplantation|May 25, 1999
Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrowA R Zander, T Zabelina, N Kröger, et al.
Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS|December 26, 2001
[Definition of shock types]H A Adams, G Baumann, A Gänsslen, et al.
European Journal of Haematology|December 14, 2005
Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre studyMartin Bornhäuser, Nicolaus Kröger, Rainer Schwerdtfeger, et al.
Bone Marrow Transplantation|August 7, 2012
Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patientsN Kröger, T Zabelina, E Klyuchnikov, et al.
Blood|September 1, 1978
Cytogenetic evidence for recurrence of acute myelogenous leukemia after allogeneic bone marrow transplantation in donor hematopoietic cellsG J Elfenbein, D S Brogaonkar, W B Bias, et al.
Annals of Hematology|March 4, 2003
Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemiaJ Schetelig, C Thiede, M Bornhäuser, et al.
Pageof 46

Showing results (411-420 of 456) with videos related to

Sort By:
Pageof 46
Blood|May 22, 2010
Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosisHaefaa Alchalby, Anita Badbaran, Tatjana Zabelina, et al.
Bone Marrow Transplantation|July 9, 2009
Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cellsM Lioznov, J El-Cheikh, F Hoffmann, et al.
Haematologica|May 25, 2011
Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myelomaDjordje Atanackovic, Jens Panse, York Hildebrandt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 29, 2008
Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-upA R Zander, C Schmoor, N Kröger, et al.
Bone Marrow Transplantation|May 25, 1999
Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrowA R Zander, T Zabelina, N Kröger, et al.
Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS|December 26, 2001
[Definition of shock types]H A Adams, G Baumann, A Gänsslen, et al.
European Journal of Haematology|December 14, 2005
Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre studyMartin Bornhäuser, Nicolaus Kröger, Rainer Schwerdtfeger, et al.
Bone Marrow Transplantation|August 7, 2012
Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patientsN Kröger, T Zabelina, E Klyuchnikov, et al.
Blood|September 1, 1978
Cytogenetic evidence for recurrence of acute myelogenous leukemia after allogeneic bone marrow transplantation in donor hematopoietic cellsG J Elfenbein, D S Brogaonkar, W B Bias, et al.
Annals of Hematology|March 4, 2003
Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemiaJ Schetelig, C Thiede, M Bornhäuser, et al.
Pageof 46